Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111036 | 0.83 | PDE2A (0.38) | DHFRSLC2A1 | |
| SCHEMBL2286007 | 0.83 | PDE10A (0.39) | DHFRSLC2A1 | |
| SCHEMBL4120161 | 0.82 | PDE10A (0.44) | — | |
| SCHEMBL4110510 | 0.81 | DHFR (0.33) | DHFRSLC2A1 | |
| SCHEMBL2286829 | 0.81 | BACE1 (0.32) | DHFRSLC2A1 | |
| SCHEMBL2289587 | 0.79 | NCF1 (0.33) | DHFRSLC2A1 | |
| SCHEMBL2289581 | 0.78 | — | — | |
| SCHEMBL4110186 | 0.78 | NQO1 (0.34) | — | |
| SCHEMBL2285500 | 0.78 | CYP1A2 (0.43) | — | |
| SCHEMBL976140 | 0.77 | CYP1A2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247571-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2009-10-01 | — | — | US | claimed |
| US-7998976-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998976-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998976-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20090247571-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090247571-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090247571-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247571-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | DHFR 1442/4885SLC2A1 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.